Boehringer Ingelheim, Sarah Cannon Research Institute deal

Boehringer and the institute partnered to develop Boehringer’s BI 754091 in combination with BI 754111 to treat cancer, including non-small cell lung cancer (NSCLC). BI 754091 is a mAb against PD-1, ...